Electronic Supplementary Material

ESM Table 1 List of human samples (**a**) Tissue samples. (**b**) Samples used for transcriptome analysis. (**c**) Samples used for T cell proliferation.

a) Tissue samples						
	Age					
Patient	(years)	Sex	Disease	Disease duration	Source	
DiViD 6	35	Male	T1D	5w	DiViD	
DiViD 5	24	Female	T1D	5w	DiViD	
DiViD 4	31	Male	T1D	5w	DiViD	
DiViD 3	34	Female	T1D	9w	DiViD	
DiViD 2	24	Male	T1D	3w	DiViD	
DiViD 1	25	Female	T1D	4w	DiViD	
28 74	52	Female	No diabetes	N/A	Exeter	
540 91	11	Male	No diabetes	N/A	Exeter	
8579	7	UNK	No diabetes	N/A	Exeter	
E560	17	Male	T1D	1w	Exeter	
E124B	42	Female	T1D	18m	Exeter	
11746	6	Male	T1D	<1w	Exeter	
1	Unknown	Unknown	No diabetes	N/A	Rigshospitalet	
2	Unknown	Unknown	No diabetes	N/A	Rigshospitalet	
3	Unknown	Unknown	No diabetes	N/A	Rigshospitalet	
b) Transcriptome analysis						
	Age					
Patient	(years)	Sex	Disease	Disease duration	Source	
6013-04PT	65	Male	No diabetes	N/A	nPOD	
6024-01PT	21	Male	No diabetes	N/A	nPOD	

6048-04PT	30	Male	No diabetes	N/A	nPOD
6075-06PB	16	Male	No diabetes	N/A	nPOD
6012-02PT	68	Female	No diabetes	N/A	nPOD
6099-02PB	14	Male	No diabetes	N/A	nPOD
6140-04PT	38	Male	No diabetes	N/A	nPOD
6162-01PT	22	Male	No diabetes	N/A	nPOD
6168-04PT	51	Male	No diabetes	N/A	nPOD
6227-02PT	17	Female	No diabetes	N/A	nPOD
6129-02PT	42.9	Female	No diabetes	N/A	nPOD
6165-04PT	45.8	Female	No diabetes	N/A	nPOD
6102-04PT	45.1	Female	No diabetes	N/A	nPOD
6229-02PT	31	Female	No diabetes	N/A	nPOD
6251-02PT	33	Female	No diabetes	N/A	nPOD
6010-04PT	47	Female	No diabetes	N/A	nPOD
6179-04B PB	21.8	Female	No diabetes	N/A	nPOD
6019-04PT	42	Male	No diabetes	N/A	nPOD
6188-06PT	36.1	Male	T2D	Unknown	nPOD
6114-03PT	42.8	Male	T2D	Unknown	nPOD
6249-01PT	45	Female	T2D	Unknown	nPOD
6275-02PT	48	Male	T2D	Unknown	nPOD
6273-04PT	45	Female	T2D	Unknown	nPOD
6191-01PT	62	Female	T2D	Unknown	nPOD
6059-06PT	18.8	Female	T2D	Unknown	nPOD
6110-05PT	20.7	Female	T2D	Unknown	nPOD
DiViD 6	35	Male	T1D	5w	DiViD
DiViD 5	24	Female	T1D	5w	DiViD
DiViD 4	31	Male	T1D	5w	DiViD

DiViD 3	34	Female	T1D	9w	DiViD			
DiViD 2	24	Male	T1D	3w	DiViD			
d) T cell prolife	d) T cell proliferation							
	Age			Disease duration				
Patient	(years)	Sex	Disease	(years)	GRS group			
55	19.6	Female	T1D	8.2	HIGH			
57	1.3	Male	T1D	0.3	INTERMEDIATE			
65	18.7	Male	T1D	16.8	INTERMEDIATE			
66	13.9	Male	T1D	8.0	INTERMEDIATE			
68	19.0	Male	T1D	4.5	INTERMEDIATE			
76	20.1	Male	T1D	16.7	LOW			
77	20.1	Male	T1D	8.1	LOW			
79	16.2	Female	T1D	3.8	INTERMEDIATE			
80	16.1	Female	T1D	11.0	HIGH			
81	13.1	Female	T1D	6.7	INTERMEDIATE			
83	18.0	Male	T1D	8.3	INTERMEDIATE			
84	16.9	Female	T1D	8.2	INTERMEDIATE			
85	39.8	Male	T1D	32.0	INTERMEDIATE			
86	12.3	Female	T1D	0.8	INTERMEDIATE			
87	11.1	Male	T1D	2.0	LOW			
88	23.1	Female	T1D	21.8	LOW			
89	23.8	Male	T1D	12.0	INTERMEDIATE			
90	24.3	Female	T1D	13.9	LOW			
01	23.8	Female	T1D	21.6	INTERMEDIATE			
02	13.7	Male	T1D	3.9	INTERMEDIATE			
02	18.4	Male	T1D	6.6	HIGH			
94	13.8	Male	T1D	0.0	HIGH			

05	21.6	Male	T1D	6.3	INTERMEDIATE
95	17.9	Female	T1D	16.2	HIGH
97	11.2	Female	T1D	0.0	INTERMEDIATE
98	13.4	Male	T1D	0.0	LOW
100	14.0	Male	T1D	12.1	HIGH
101	11.7	Female	T1D	0.1	INTERMEDIATE
103	13.6	Male	T1D	0.1	INTERMEDIATE
104	19.5	Male	T1D	4.6	INTERMEDIATE
105	13.3	Female	T1D	0.0	HIGH
106	18.7	Male	T1D	13.0	INTERMEDIATE
107	19.9	Male	T1D	14.3	LOW
108	10.4	Female	T1D	0.0	HIGH
109	5.9	Male	T1D	0.0	HIGH
110	16.4	Female	T1D	11.2	INTERMEDIATE
111	19.5	Female	T1D	11.6	INTERMEDIATE
112	18.8	Male	T1D	16.2	LOW
113	16.7	Male	T1D	6.0	INTERMEDIATE
114	17.2	Male	T1D	0.2	HIGH
115	22.6	Female	T1D	12.3	HIGH
125	15.4	Male	T1D	0.0	INTERMEDIATE
127	11.4	Female	T1D	8.4	INTERMEDIATE
129	17.1	Female	T1D	10.1	LOW
134	20.7	Male	T1D	10.2	HIGH
135	13.6	Male	T1D	1.5	INTERMEDIATE
136	20.8	Female	T1D	11.5	LOW
137	21.4	Male	T1D	19.2	LOW
138	21.3	Male	T1D	Unknown	INTERMEDIATE

	19.3	Female	T1D	6.1	INTERMEDIATE
139	10.0				
140	18.8	Male	T1D	Unknown	LOW
140	14.2	Male	T1D	83	LOW
141	17.2	iviaic	TID	0.5	LOW
	14.5	Male	T1D	6.8	LOW
142					
1.42	29.1	Female	T1D	5.7	LOW
143	24.2	Eamala	T1D	25.4	LOW
144	34.5	remaie	TID	23.4	LOW
	34.9	Female	T1D	0.0	LOW
145					
	18.0	Male	T1D	3.0	INTERMEDIATE
147					
140	8.8	Female	TID	0.0	INTERMEDIATE
140	23.9	Male	T1D	12.5	INTERMEDIATE
149	23.7	iviaic	TID	12.5	INTERNEDITE
	18.1	Male	T1D	5.9	LOW
150					
	14.6	Male	T1D	1.1	INTERMEDIATE
152	10.2	F 1	T1D	TT 1	
153	18.3	Female	TID	Unknown	INTERMEDIATE
155	23.5	Male	T1D	20.8	INTERMEDIATE
154	2010	1110110		2010	
	21.3	Female	T1D	12.9	INTERMEDIATE
155					
156	29.6	Female	T1D	Unknown	LOW
156	1/1.0	Male	T1D	7.0	INTERMEDIATE
157	14.7	Iviaic	ПD	1.3	
	6.6	Male	T1D	0.1	LOW
159					
	20.6	Female	T1D	16.8	HIGH
160	10.0	D 1	T 1D	0.1	
161	10.3	Female	TID	0.1	INTERMEDIATE
101	18.9	Male	T1D	84	INTERMEDIATE
162	10.7	Iviaic		0.4	
	13.7	Female	T1D	0.0	HIGH
163					



ESM Fig. 1 Sulfatide is present in beta cells and not alpha cells. Immunofluorescent staining of a healthy pancreas sections showing that sulfatide is expressed in beta cells and occasionally in cells negative for both insulin and glucagon. Scale bar, $10 \,\mu$ m.



ESM Fig. 2 Overview of the altered RNA expression in pancreatic islets of individuals with newly diagnosed type 1 diabetes vs control participants. The enzymes are listed next to the catalytic reaction they are involved in. It should be noted that some enzymes catalyze more reactions than shown here. The number after the enzymes name represents the change in percent followed by the p value. The difference in expression is showed for genes with a p value <0.05. No difference between control participants and individuals with type 2 diabetes for the selected genes. One-way ANOVA with Tukey's multiple comparisons test.

3-ketodihydrosphingosine reductase (*KDSR*); Δ 4-dihydroceramide desaturase (*DEGS*); Galactosylceramide (GalCer); N-acylsphingosine amidohydrolase (*ASAH*); sphingomyelin (SM); C1P, ceramide-1-phosphate; S1P, sphingosine-1-phosphate; alkaline ceramidase (*ACER*); sphingomyelin synthase (*SGMS*); sphingosine kinase (*SPHK*): cerebroside sulfotransferase (*CST*); galactosylceramidase (*GALC*); glucosylceramide (GlcCer); lactosylceramide (LacCer); pleckstrin homology domain containing A8 (*FAPP2* or *PLEKHA8*); ceramide transfer protein (*CERT*); VPS, GARP, complex subunit (*VPS*). solute carrier family (*SLC*); GM2 ganglioside activator (*GM2A*); beta-1,3-galactosyltransferase (*B3GALT*); beta-1,4-galactosyltransferase (*B4GALT*); lactotriaosylceramide (Lc3); UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase (*B3GNT*); alpha 1,4-galactosyltransferase (*A4GALT*); beta-1,4-N-acetyl-galactosaminyltransferase (*B4GALNT*); galactose- α 2,3-sialyltransferase (*ST3GALT*); phosphoglycerate dehydrogenase (*PGDH*); phosphoserine aminotransferase (*PSAT*); phosphoserine phosphatase (*PSP*)



ESM Fig. 3 Ranked non-HLA loci associated with type 1 diabetes. Red bars represent genes identified in this study. List of genes taken from [1].

[1] Concannon P, Rich SS, Nepom GT (2009) Genetics of type 1A diabetes. N Engl J Med 360: 1646-1654